Abcam webinar agenda

Abcam Webinar Agenda

Unlocking the True Value of Multiplexing IHC – From Clinical Trial Programs Through to IVD Applications

12:00 pm Introduction by Hanson Wade

12:05 pm Presentation: The Value of Using mIHC for Clinical Trials Through to IVD Applications

  • Will Howat Senior Director of Antibody Validation & Characterization, Abcam

Synopsis

  • The potential and promise of mIHC for routine clinical application
  • Challenges of getting your mIHC ready for IVD use and how to overcome them
  • The value of the right content to fuel mIHC and the importance of reagent and panel validation

12:15 pm Presentation: Robust & Seep up Use of mIHC in Clinical Trial Settings

  • Angela Vasaturo Associate Director Biomarker Strategy and Applications, Ultivue

Synopsis

  • Overcoming key barriers to large-scale adoption and application of mIHC in clinical settings
  • How pharma can be supported with content, assay development and assay deployment to speed up use of mIHC in clinical trial settings
  • Key takeaways from how pharma is currently employing this technology and where to go next

12:25 pm Presentation: Moving Multiplex IF Into Clinical Trials

Synopsis

  • Fit for Purpose Validation of IF protocols for clinical trial applications
  • Combining requirements from laboratory, pathology, digital imaging and data management under GCP
  • From sample receipt to result transfer: critical steps from a CRO’s perspective

12:35 pm Panel + Q&A: Reaching New Heights by Working Together: How Abcam, Ultivue & Targos Builds Robust Partnership Chain & Support with Pharma from Clinical Trials Through to IVD

  • Angela Vasaturo Associate Director Biomarker Strategy and Applications, Ultivue
  • Will Howat Senior Director of Antibody Validation & Characterization, Abcam
  • Oliver Stoss Chief Executive Officer, Targos Inc.
  • Keith Wharton VP Medical Director, Ultivue

Synopsis

  • How our commitment to the highest standards in immune-oncology, cancer and neuroscience diagnostics adds value to your work
  • We understand your specific needs and our robust partnership process can help you rapidly advance the key stages of your mIHC from analytical validation to demonstration of clinical utility and all the way through to IVD application
  • How we can help with successful global deployment and seamless incorporation of this technology into your process for robust and reproducible large-scale adoption

1:00 pm End of Webinar Hosted by Abcam

APPLY TO ATTEND